SBIR Phase II: Optimization of Rotavirus Vaccine Production

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 200-2014-61232
Agency Tracking Number: 200-2014-61232
Amount: $1,144,845.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-09-29
Award End Date (Contract End Date): 2015-12-31
Small Business Information
3471 Pines Hill Dr., Cincinnati, OH, 45244-
DUNS: 066132549
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Victor  VanCleave
 (858) 565-4227
 Victor.VanCleave@MeridianLifescience.com
Business Contact
 Victor  VanCleave
Phone: (858) 565-4227
Email: Victor.VanCleave@MeridianLifescience.com
Research Institution
N/A
Abstract
To improve the safety and efficacy of oral rotavirus vaccines, CDC scientists have developed a proprietary inactivated rotavirus vaccine (IRV) technology (new human strains and a novel method for rotavirus inactivation) and demonstrated the immunogenicity in mice [14] and protective efficacy in piglets [15] of this IRV by intramuscular (IM) administration. More recently, CDC scientists have demonstrated enhanced immunogenicity of IRV using an innovative microneedle patch technology, achieving comparable antibody titers with a 1/10th of the antigen dose compared to those induced by a full IM dose of vaccine. Microneedles provide a simple and painless method to administer vaccines without using hypodermic needles. They are inexpensive to manufacture and may not require a cold chain for storage and transport, a major advantage for immunization campaigns in the developing world. With the establishment of proof of concept for IM and skin immunization in animals, CDC has entered an agreement with Meridian Life Science (MLS) to produce a master virus bank (MVB) under Good Manufacturing Practice (GMP) conditions at the MLS facilities in Memphis, Tennessee. Based on the results and progress from the Phase I SBIR contract, the phase II contract will focus on preparation of inactivated rotavirus vaccine pilot lots for phase I clinical trials.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government